AbbVie’s Humira, Six Other Drugs Saw Unsupported Price Hikes in 2020, ICER Says

AbbVie’s rheumatoid arthritis drug Humira (adalimumab) and six other drugs whose prices were raised in 2020 without supportive clinical data cost the U.S. health system $1.67 billion in annual drug spending, according to a new analysis released yesterday by the Institute for Clinical and Economic Review (ICER).
Source: Drug Industry Daily